Message frequency may vary. You may opt out at any time.
Terms of Use and Privacy Policy

Videos

Watch to learn more about Rayaldee, CKD, and SHPT.

Rayaldee Reimbursement Navigation Guide for Healthcare Providers

What Is OPKO Connect, and How Can It Help My Patients Receive Rayaldee?

Mechanism of Action of Rayaldee^® (calcifediol)

Management of Secondary Hyperparathyroidism: a Patient Case (Presented by Dr. Stuart Sprague, DO, FACP, FASN, FNKF)

The Vitamin D Debate in CKD and SHPT: How High Should We Aim? (ASN Kidney Week 2019 in Washington, DC)

Rationale for Raising Current Clinical Practice Guideline Targets for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease (RPA Satellite Symposium 2019)

Transcript

Rayaldee Capsule Extended-Release Formulation

Important Safety Information

•	Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
•	Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
•	Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
•	The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
•	Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
•	Serum calcium should be below 9.8 mg/dL before initiating treatment.
•	Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.

Indication and Limitations of Use

Rayaldee^® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

Important Safety Information

•	Hypercalcemia: Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
•	Digitalis toxicity: Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
•	Adynamic Bone Disease: Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
•	The most common adverse reactions (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
•	Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
•	Serum calcium should be below 9.8 mg/dL before initiating treatment.
•	Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

Please see Full Prescribing Information.

Sign up to be notified about Rayaldee news.

Videos

Important Safety Information

Indication and Limitations of Use

Important Safety Information